Alder Biopharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Alder Biopharmaceuticals Inc. thinks its manufacturing methods, which utilize Pichia yeast, can overcome a number of the key challenges that companies currently encounter when producing antibodies in mammalian cells. Alder has made genetic mutations so that the yeast manufacture antibodies without any attached sugar groups. These a-glycosylated antibodies will be able to treat diseases where antigen neutralization vs. outright cell killing is sufficient to get a therapeutic effect.
You may also be interested in...
The Next-Generation Antibody Players
A host of companies are vying to develop new and improved antibodies. Technologies span the gamut from improving ADCC effector function to stripping away components of traditional antibodies to create leaner molecules that may be cheaper to manufacture and eaiser to deliver orally. These start-ups remain product focused, eschewing the platform technology model. Pharmaceutical and established biotechnology companies are eager to get their hands on the technologies, causing a flurry of deal-making in the last year.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Spero Therapeutics: Remodeling Antibiotics
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.